Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis

D. O. Clegg; D. J. Reda; E. Mejias; G. W. Cannon; M. H. Weisman; T. Taylor; E. Budiman-Mak; W. D. Blackburn; F. B. Vasey; M. L. Mahowald; J. J. Cush; H. R. Schumacher; S. L. Silverman; F. P. Alepa; M. E. Luggen; M. R. Cohen; R. Makkena; C. M. Haakenson; R. H. Ward; B. J. Manaster; R. J. Anderson; J. R. Ward; W. G. Henderson

doi:10.1002/art.1780391210

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis

D. O. Clegg, D. J. Reda, E. Mejias, G. W. Cannon, M. H. Weisman, T. Taylor, E. Budiman-Mak, W. D. Blackburn, F. B. Vasey, M. L. Mahowald, J. J. Cush, H. R. Schumacher, S. L. Silverman, F. P. Alepa, M. E. Luggen, M. R. Cohen, R. Makkena, C. M. Haakenson, R. H. Ward, B. J. ManasterR. J. Anderson, J. R. Ward, W. G. Henderson

Medicine - Veteran's Administration Medical Center

Research output: Contribution to journal › Review article › peer-review

441 Scopus citations

Abstract

Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory drug therapy. Methods. Two hundred twenty-one patients with PsA were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on joint pain/ tenderness and swelling scores and physician and patient global assessments. Results. Longitudinal analysis revealed a trend favoring SSZ treatment (P = 0.13). At the end of treatment, response rates were 57.8% for SSZ compared with 44.6% for placebo (P = 0.05). The Westergren erythrocyte sedimentation rate declined more in the PsA patients taking SSZ than in those taking placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints, including dyspepsia, nausea, vomiting, and diarrhea. Conclusion. SSZ at a dosage of 2,000 mg/day is well tolerated and may be more effective than placebo in the treatment of patients with PsA.

Original language	English (US)
Pages (from-to)	2013-2020
Number of pages	8
Journal	Arthritis and rheumatism
Volume	39
Issue number	12
DOIs	https://doi.org/10.1002/art.1780391210
State	Published - Dec 1996

Publisher link

10.1002/art.1780391210

Find It

Find It at U of M Libraries

Cite this

Clegg, D. O., Reda, D. J., Mejias, E., Cannon, G. W., Weisman, M. H., Taylor, T., Budiman-Mak, E., Blackburn, W. D., Vasey, F. B., Mahowald, M. L., Cush, J. J., Schumacher, H. R., Silverman, S. L., Alepa, F. P., Luggen, M. E., Cohen, M. R., Makkena, R., Haakenson, C. M., Ward, R. H., ... Henderson, W. G. (1996). Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. Arthritis and rheumatism, 39(12), 2013-2020. https://doi.org/10.1002/art.1780391210

Clegg, DO, Reda, DJ, Mejias, E, Cannon, GW, Weisman, MH, Taylor, T, Budiman-Mak, E, Blackburn, WD, Vasey, FB, Mahowald, ML, Cush, JJ, Schumacher, HR, Silverman, SL, Alepa, FP, Luggen, ME, Cohen, MR, Makkena, R, Haakenson, CM, Ward, RH, Manaster, BJ, Anderson, RJ, Ward, JR & Henderson, WG 1996, 'Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis', Arthritis and rheumatism, vol. 39, no. 12, pp. 2013-2020. https://doi.org/10.1002/art.1780391210

@article{0846efd805f74e81a14ff68196da080a,

title = "Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis",

abstract = "Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory drug therapy. Methods. Two hundred twenty-one patients with PsA were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on joint pain/ tenderness and swelling scores and physician and patient global assessments. Results. Longitudinal analysis revealed a trend favoring SSZ treatment (P = 0.13). At the end of treatment, response rates were 57.8% for SSZ compared with 44.6% for placebo (P = 0.05). The Westergren erythrocyte sedimentation rate declined more in the PsA patients taking SSZ than in those taking placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints, including dyspepsia, nausea, vomiting, and diarrhea. Conclusion. SSZ at a dosage of 2,000 mg/day is well tolerated and may be more effective than placebo in the treatment of patients with PsA.",

author = "Clegg, {D. O.} and Reda, {D. J.} and E. Mejias and Cannon, {G. W.} and Weisman, {M. H.} and T. Taylor and E. Budiman-Mak and Blackburn, {W. D.} and Vasey, {F. B.} and Mahowald, {M. L.} and Cush, {J. J.} and Schumacher, {H. R.} and Silverman, {S. L.} and Alepa, {F. P.} and Luggen, {M. E.} and Cohen, {M. R.} and R. Makkena and Haakenson, {C. M.} and Ward, {R. H.} and Manaster, {B. J.} and Anderson, {R. J.} and Ward, {J. R.} and Henderson, {W. G.}",

year = "1996",

month = dec,

doi = "10.1002/art.1780391210",

language = "English (US)",

volume = "39",

pages = "2013--2020",

journal = "Arthritis and rheumatism",

issn = "0004-3591",

publisher = "John Wiley and Sons Ltd",

number = "12",

}

TY - JOUR

T1 - Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis

AU - Clegg, D. O.

AU - Reda, D. J.

AU - Mejias, E.

AU - Cannon, G. W.

AU - Weisman, M. H.

AU - Taylor, T.

AU - Budiman-Mak, E.

AU - Blackburn, W. D.

AU - Vasey, F. B.

AU - Mahowald, M. L.

AU - Cush, J. J.

AU - Schumacher, H. R.

AU - Silverman, S. L.

AU - Alepa, F. P.

AU - Luggen, M. E.

AU - Cohen, M. R.

AU - Makkena, R.

AU - Haakenson, C. M.

AU - Ward, R. H.

AU - Manaster, B. J.

AU - Anderson, R. J.

AU - Ward, J. R.

AU - Henderson, W. G.

PY - 1996/12

Y1 - 1996/12

N2 - Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory drug therapy. Methods. Two hundred twenty-one patients with PsA were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on joint pain/ tenderness and swelling scores and physician and patient global assessments. Results. Longitudinal analysis revealed a trend favoring SSZ treatment (P = 0.13). At the end of treatment, response rates were 57.8% for SSZ compared with 44.6% for placebo (P = 0.05). The Westergren erythrocyte sedimentation rate declined more in the PsA patients taking SSZ than in those taking placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints, including dyspepsia, nausea, vomiting, and diarrhea. Conclusion. SSZ at a dosage of 2,000 mg/day is well tolerated and may be more effective than placebo in the treatment of patients with PsA.

AB - Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory drug therapy. Methods. Two hundred twenty-one patients with PsA were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on joint pain/ tenderness and swelling scores and physician and patient global assessments. Results. Longitudinal analysis revealed a trend favoring SSZ treatment (P = 0.13). At the end of treatment, response rates were 57.8% for SSZ compared with 44.6% for placebo (P = 0.05). The Westergren erythrocyte sedimentation rate declined more in the PsA patients taking SSZ than in those taking placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints, including dyspepsia, nausea, vomiting, and diarrhea. Conclusion. SSZ at a dosage of 2,000 mg/day is well tolerated and may be more effective than placebo in the treatment of patients with PsA.

UR - http://www.scopus.com/inward/record.url?scp=2042519830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2042519830&partnerID=8YFLogxK

U2 - 10.1002/art.1780391210

DO - 10.1002/art.1780391210

M3 - Review article

C2 - 8961906

AN - SCOPUS:2042519830

SN - 0004-3591

VL - 39

SP - 2013

EP - 2020

JO - Arthritis and rheumatism

JF - Arthritis and rheumatism

IS - 12

ER -

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis

Abstract

Publisher link

Find It

Other files and links

Fingerprint

Cite this